Complement Activation

• 

  Subject Areas on Research

  • A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition. 
  • A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. 
  • Acquired C1 esterase inhibitor deficiency and angioedema: a review. 
  • Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. 
  • Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid Arthritis. 
  • Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. 
  • Activation of the C3b receptor: effect of diacylglycerols and calcium mobilization. 
  • Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. 
  • Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. 
  • Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. 
  • Aging and stress-induced changes in complement activation and neutrophil mobilization. 
  • An auto-anti-M causing hemolysis in vitro. 
  • Anaphylactic and anaphylactoid reactions. A review. 
  • Annihilating host defense. 
  • Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. 
  • Behçet's disease patients present high levels of deglycosylated anti-lipoteichoic acid IgG and high IL-8 production after lipoteichoic acid stimulation. 
  • Beyond Viral Neutralization. 
  • Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. 
  • Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. 
  • Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. 
  • Bypassing complement: evolutionary lessons and future implications. 
  • C1-esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle. 
  • C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae. 
  • CD19 can regulate B lymphocyte signal transduction independent of complement activation. 
  • CR1-receptor recycling in phorbol ester-activated polymorphonuclear leucocytes. 
  • Carbamylation of immunoglobulin abrogates activation of the classical complement pathway. 
  • Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. 
  • Characterization and affinity isolation of xenoreactive human natural antibodies. 
  • Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. 
  • Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. 
  • Complement activation and cardiac surgery: a novel target for improving outcomes. 
  • Complement activation contributes to perioperative neurocognitive disorders in mice. 
  • Complement activation influences Staphylococcus aureus adherence to endothelial cells. 
  • Complement and bacteria: chemistry and biology in host defense. 
  • Complement disorders and hereditary angioedema. 
  • Complement factor H variant increases the risk of age-related macular degeneration. 
  • Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. 
  • Complement levels and activity in the normal and LPS-injured lung. 
  • Complement receptors. 
  • Complement system in lung transplantation. 
  • Complement-Mediated Regulation of Apolipoprotein E in Cultured Human RPE Cells. 
  • Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. 
  • Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. 
  • Complement: a brief review. 
  • Component deficiencies. 5. The fifth component. 
  • Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. 
  • Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system. 
  • Diagnosis and treatment of anaphylactic/anaphylactoid reactions. 
  • Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. 
  • Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. 
  • Dual islet transplantation modeling of the instant blood-mediated inflammatory reaction. 
  • Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Effects of chronic mild stress on serum complement activity, saccharin preference, and corticosterone levels in Flinders lines of rats. 
  • Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. 
  • Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis. 
  • Generation of a fibroblast chemotactic factor in serum by activation of complement. 
  • Genetic therapies for xenotransplantation. 
  • Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. 
  • Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. 
  • Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. 
  • IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. 
  • Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. 
  • Immunoglobulin in the control of complement action. 
  • Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. 
  • Inhaled asbestos activates a complement-dependent chemoattractant for macrophages. 
  • Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. 
  • Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury. 
  • Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. 
  • Intramolecular immunological signal hypothesis revived--structural background of signalling revealed by using Congo Red as a specific tool. 
  • Isolation and characterization of a novel plasma protein which binds to activated C4 of the classical complement pathway. 
  • Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation. 
  • Lymphocyte phenotypes in wild-caught rats suggest potential mechanisms underlying increased immune sensitivity in post-industrial environments. 
  • Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. 
  • Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. 
  • Microparticles as autoantigens: making immune complexes big. 
  • Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. 
  • Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. 
  • Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. 
  • NIH conference. Primary biliary cirrhosis and the complement system. 
  • New developments in immunopathology with special reference to complement and immune complexes. 
  • Next-generation computational genetic analysis: multiple complement alleles control survival after Candida albicans infection. 
  • Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. 
  • Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. 
  • Nrf2 signaling modulates cigarette smoke-induced complement activation in retinal pigmented epithelial cells. 
  • Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation. 
  • Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. 
  • Production and characterization of the monoclonal antibody against SGP120, a novel serum protein. 
  • Protease inhibitors of human plasma. C1-inhibitor (C1-INH). 
  • Quantitation of activation of the human terminal complement pathway by ELISA. 
  • Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. 
  • Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. 
  • Regulation of complement activity by vaccinia virus complement-control protein. 
  • Regulation of humoral immune responses by CD21/CD35. 
  • Role of C3 cleavage in monocyte activation during extracorporeal circulation. 
  • Role of complement activation in a model of adult respiratory distress syndrome. 
  • Role of complement activation in obliterative bronchiolitis post-lung transplantation. 
  • Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. 
  • Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. 
  • Serum complement activation in central nervous system disease in Sjögren's syndrome. 
  • Studies of antibody and complement function in host defense against bacterial infection. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. 
  • Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. 
  • Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. 
  • The complement system in host defense and inflammation. 
  • The genome of the sea urchin Strongylocentrotus purpuratus. 
  • The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3. 
  • The immune consequences of trauma. 
  • The inflammatory response to cardiopulmonary bypass. 
  • The pathogenesis of dermatitis herpetiformis. 
  • The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. 
  • The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. 
  • The role of the spleen in experimental pneumococcal bacteremia. 
  • The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway. 
  • Therapeutic potential of complement modulation. 
  • V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. 
  • Venous gas emboli and complement activation after deep repetitive air diving. 
  • Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. 
  • Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. 
  • beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. 
• 

  Keywords of People

  • Ali, Hakim Azfar, Assistant Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine
  • Kelsoe, Garnett H., James B. Duke Professor of Immunology, Immunology
  • Wray, Gregory Allan, Professor of Biology, Duke Innovation & Entrepreneurship